Abstract Details

Title Long-Term Efficacy of Fremanezumab in Patients With Chronic Migraine With Concomitant Preventive Medication Use

Topic Headache

Presentation(s) P1 - Poster Session 1 (5:30 PM-6:30 PM)

Poster/Presentation
Number 13-008

Objective To evaluate the long-term efficacy of fremanezumab in adults with chronic migraine (CM) with concomitant preventive medication use.

Background Migraine preventive treatment is intended to reduce the frequency, severity, and disability of migraine attacks. Fremanezumab, a fully humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP), is approved in the US for the preventive treatment of migraine.

Design/Methods In this 52-week, multicenter, randomized, double-blind, parallel-group study, patients with CM received either subcutaneous fremanezumab monthly (225 mg every month with a starting dose of 675 mg) or quarterly (675 mg every 3 months). The mean change from baseline was assessed for the monthly average number of headache days of at least moderate severity and migraine days, as was the percentage of patients with ≥50% or ≥75% reduction in the monthly average number of migraine days.

Results A total of 268 patients used concomitant preventive medications, the most common of which were topiramate (37%), amitriptyline (18%), and propranolol (11%). Headache days of at least moderate severity decreased from baseline of the blinded phase (mean quarterly 14.2 days, monthly 14.7 days) to Month 12 by 5.9 days in the quarterly group and 6.1 days in the monthly group. The mean change in the monthly average number of migraine days from baseline to Month 12 was –6.9 days for quarterly and –6.8 days for monthly dosing. The proportion of patients with ≥50% reduction in migraine days at Month 12 was 52.5% for quarterly and 47.7% for monthly dosing. The proportion of patients with ≥75% reduction in migraine days at Month 12 was 19.8% for quarterly and 24.3% for monthly dosing.

Conclusions The efficacy of fremanezumab was maintained over 12 months of treatment in patients with CM with concomitant preventive medication use.

Authors/Disclosures
Paul P. Yeung, MD, PhD PRESENTER	No disclosure on file
Peter Goadsby, MD, PhD, FRS (King Abdullah Univeristy of Science and Technology)	Dr. Goadsby has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Abbvie. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva Pharmaceuticals. Dr. Goadsby has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lundbeck. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Satsuma. Dr. Goadsby has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shiratronics. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CoolTech LLC. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Linpharma. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for PureTech Health LLC. Dr. Goadsby has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Kallyope. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Seaport Therapeutics. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Dr Reddy's. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Orion Pharma. Dr. Goadsby has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Ipsen. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Massachusetts Medical Society. The institution of Dr. Goadsby has received research support from NIHR. Dr. Goadsby has received publishing royalties from a publication relating to health care. Dr. Goadsby has received publishing royalties from a publication relating to health care. Dr. Goadsby has a non-compensated relationship as a Trustee with Migraine Trust that is relevant to AAN interests or activities. Dr. Goadsby has a non-compensated relationship as a Trustee with Organisation for Understanding Cluster Headache (UK) that is relevant to AAN interests or activities.
Adelene Jann, MD (NYU Langone Health)	Dr. Jann has nothing to disclose.
	No disclosure on file
	No disclosure on file
Xiaoping Ning (Teva pharmaceuticals)	Ms. Ning has received personal compensation for serving as an employee of Teva Pharmaceutical . Ms. Ning has received personal compensation for serving as an employee of Teva Pharmaceutical.

��ɫ��

��ɫ��